Department of Orthopedics Surgery, Fujian Medical University Union Hospital, Fuzhou, 350001, Fujian, China.
Department of Emergency, Zhaotong Traditional Chinese Medicine Hospital, Zhaotong, 657000, Yunnan, China.
Eur Spine J. 2021 Sep;30(9):2691-2697. doi: 10.1007/s00586-021-06899-w. Epub 2021 Jun 16.
In order to prevent the recurrent fracture after vertebral augmentation, the concept of prophylactic vertebral augmentation has been proposed, but its efficacy is still controversial. This study aimed to determine the efficacy of prophylactic vertebral augmentation for prevention of refracture in osteoporotic vertebral fracture patients.
Following PRISMA guidelines, a literature search was performed using PubMed, Embase and Web of Science databases for relevant studies published until February 2021. A meta-analysis of randomized controlled trials and retrospective controlled trials comparing prophylactic group versus nonprophylactic group was conducted. The primary outcome was the incidence of new vertebral compression fracture (VCF), and secondary outcomes were incidence of adjacent vertebral fracture (AVF) and remote vertebral fracture (RVF).
A total of 6 studies encompassing 618 patients were included in the meta-analysis. The incidence of new VCF was reported in all six studies, and the result showed no significant difference between the two groups (OR: 0.509; 95% CI: 0.184-1.409). Four studies provided data on the incidence of AVF, and it was revealed that there was no significant difference between the two groups (OR: 0.689; 95% CI: 0.109-4.371). In view of the incidence of RVF, prophylactic group also did not differ significantly compared with nonprophylactic group (OR: 0.535; 95% CI: 0.167-1.709).
The current evidence suggested that prophylactic vertebral augmentation might not be appropriate to diminish the risk of new VCF. Therefore, there is a need to investigate the mechanism of refracture and explore other preventive regimens to reduce the risk.
为了防止椎体增强后再次发生骨折,提出了预防性椎体增强的概念,但疗效仍存在争议。本研究旨在确定预防性椎体增强治疗对骨质疏松性椎体骨折患者预防再骨折的疗效。
根据 PRISMA 指南,通过 PubMed、Embase 和 Web of Science 数据库对截至 2021 年 2 月发表的相关研究进行文献检索。对比较预防性组与非预防性组的随机对照试验和回顾性对照试验进行荟萃分析。主要结局是新发椎体压缩性骨折(VCF)的发生率,次要结局是新发相邻椎体骨折(AVF)和新发远处椎体骨折(RVF)的发生率。
共有 6 项研究纳入 618 例患者,进行荟萃分析。6 项研究均报告了新发 VCF 的发生率,结果显示两组之间无显著差异(OR:0.509;95%CI:0.184-1.409)。4 项研究提供了新发 AVF 的发生率数据,结果显示两组之间无显著差异(OR:0.689;95%CI:0.109-4.371)。关于新发 RVF 的发生率,预防性组与非预防性组也无显著差异(OR:0.535;95%CI:0.167-1.709)。
目前的证据表明,预防性椎体增强可能无法降低新发 VCF 的风险。因此,有必要探讨再骨折的机制,并探索其他预防方案以降低风险。